**ImmunityBio ANKTIVA Patient Support Services Page**

ImmunityBio is Here to Support You Throughout Your Treatment

The ImmunityBio CARE™ program is designed to help patients access ImmunityBio’s innovative treatment for BCG-unresponsive NMIBC CIS. The program offers services and resources to determine if your insurance covers ANKTIVA, including benefits investigation, prior authorization support and tracking, coding and billing assistance, claim denial guidance and payer specific appeal assistance.

More information for patients and healthcare professionals is available on Anktiva.com or 1-877-ANKTIVA (1-877-265-8482).

IMPORTANT SAFETY INFORMATION

Please see Important Safety Information throughout and full **Prescribing Information** (Link https://anktiva.com/wp-content/uploads/ANKTIVA-Annotated-Approved-Label-Clean.pdf) for ANKTIVA

References

1. Chamie, K. et al. IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. New England Journal of Medicine (NEJM) Evidence. 2023 Jan;2(1):EVIDoa2200167. <https://pubmed.ncbi.nlm.nih.gov/38320011/>

2. U.S. Food and Drug Administration (FDA). FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive nonmuscle invasive bladder cancer. U.S. FDA April 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/ fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer

3. Grabe-Heyne, K. et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Frontiers in Oncology Jun 2 2023; 13: 1170124. doi: 10.3389/fonc.2023.1170124. https://www.ncbi.nlm.nih. gov/pmc/articles/PMC10272547/

4. Koder, A. et al. The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. Cureus. 2023 Jun; 15(6): e40962. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369196/>

5. ImmunityBio, Inc. A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer. www.clinicaltrials.gov. NCT02138734